---
title: "U.S. Stock Market News | Weight-loss drug Zepbound expected to be approved in Japan next year, Eli Lilly up more than 1%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/216588859.md"
description: "On Friday, Eli Lilly's stock price fluctuated upwards, rising by 1.18% to $921.435 at the time of publication. On the news front, Eli Lilly's CEO stated on Friday that the weight loss drug Zepbound is expected to be approved in Japan next year"
datetime: "2024-10-11T15:01:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/216588859.md)
  - [en](https://longbridge.com/en/news/216588859.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/216588859.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/216588859.md) | [繁體中文](https://longbridge.com/zh-HK/news/216588859.md)


# U.S. Stock Market News | Weight-loss drug Zepbound expected to be approved in Japan next year, Eli Lilly up more than 1%

According to the Smart Finance app, on Friday, Eli Lilly (LLY.US) stock price fluctuated upwards, rising by 1.18% to $921.435 at the time of publication. On the news front, Eli Lilly's CEO stated on Friday that the weight-loss drug Zepbound is expected to be approved in Japan next year

### Related Stocks

- [Eli Lilly and Company (LLY.US)](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

- [FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market](https://longbridge.com/en/news/281394441.md)
- [BUZZ-Street View: Lilly's $7.8 billion Centessa buyout validates sleep‑drug market](https://longbridge.com/en/news/281367948.md)
- [5 Simple ETFs to Buy With $1,000 and Hold for a Lifetime](https://longbridge.com/en/news/281345615.md)
- [BUZZ-Rosenblatt says finding partner for Snap's smart glasses unit tough](https://longbridge.com/en/news/281357569.md)
- [BUZZ-Street View: Nike's turnaround remains work in progress](https://longbridge.com/en/news/281331333.md)